Zimbabwe has rejected a major American healthcare agreement worth 367 million US dollars (272 million pounds) over five years because of the United States' demand for sensitive data.
The decision was revealed after a official document from December was leaked, which showed President Emmerson Mnangagwa felt the deal was "lopsided".
A government spokesperson has since clarified that the US was seeking health data for research and commercial purposes but was unwilling to share the resulting advantages from future vaccines.
"We are forced to start the challenging and unfortunate process of scaling back our support in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy noted the United States had donated over $1.9bn for health programmes to Zimbabwe over the last two decades.
A physicians' group in Zimbabwe has appealed for continued talks to reach a deal suitable to both sides so the nation's vital HIV programme can proceed.
Broader Background
This rejection comes after a comparable case in neighbouring Kenya, where a court halted a related deal with the US following concerns were filed about the security of Kenyans' health data.
After returning to office recently, US President Donald Trump has slashed foreign aid and shut down the key foreign aid agency.
USAID had administered assistance for the US government, but Trump claimed its spending was "inefficient" and his administration was seeking direct bilateral agreements to boost openness and responsibility.
Based on reports, Sixteen nations in Africa have so far agreed to similar agreements, representing over $18.3bn in committed funds.
Details of the Rejected Deal
The funds for Zimbabwe would have supported "HIV/Aids treatment and prevention, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"It is our view this partnership could have provided immense benefits for the people of Zimbabwe, especially the 1.2 million men, women and children presently on antiretroviral therapy via American-funded programmes," the Ambassador added.
However, government spokesperson Nick Mangwana said the proposed deal was "unequal".
"The proposal required Zimbabwe to surrender its genetic material and health information for a long time, with no equivalent promise of benefiting from any medical innovations – such as new medicines or tests – that could be developed from that provided information," his statement read.
"Put simply, our nation would supply the raw materials for medical research with no assurance that the final treatments would be available to our population should a future disease outbreak emerge."
Sovereignty and Global Health
He also said that the American exit from the global health body and its pursuit of bilateral deals were upending frameworks already set up through the international organization.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing framework designed to manage potential pandemics.
"This mechanism is intended to ensure that when a nation provides its samples, the resulting advantages – such as vaccines and treatments – are shared equitably, not monopolised exclusively by those with the funds to develop them."
These objections regarding the US deal "must not be interpreted as opposition to America," he added.
"We are open to ongoing discussions with our US partners on how future collaboration might be structured in a manner that respects the independence and interests of each country."
Medical Community Reaction
A leading public health body stated it acknowledged the government's concerns, but suggested that negotiations need to persist given that much of the country's HIV programmes were funded by international support.
"If technical issues arise, such as those involving information security or implementation frameworks, these can often be resolved through detailed discussion and mutually agreed protections," the group added.
This impasse highlights the continuing tensions between accepting much-needed foreign assistance and safeguarding local interests in an increasingly data-driven world.